Allarity Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
ALLR$0.91-3.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except for share and per share data)*
| 2024 | 2023 | |
|---|---|---|
| Operating expenses: | ||
| Research and development | $6,096 | $7,103 |
| Impairment of intangible assets | 9,703 | — |
| General and administrative | 11,442 | 10,026 |
| Total operating expenses | 27,241 | 17,129 |
| Loss from operations | (27,241) | (17,129) |
| Other income (expense) | ||
| Interest income | 533 | 22 |
| Interest expenses | (653) | (498) |
| Foreign exchange gains (losses) | (212) | 133 |
| Fair value of inducement warrants | — | (4,189) |
| Loss on modification of warrants | — | (591) |
| Change in fair value adjustment of warrant derivative liabilities | 2,677 | 10,434 |
| Total other income | 2,345 | 5,311 |
| Loss before income tax expense (benefit) | (24,896) | (11,818) |
| Income tax expense (benefit) | (381) | 83 |
| Net loss | (24,515) | (11,901) |
| Deemed dividends on Series A Preferred Stock | (299) | (8,392) |
| Deemed dividend on Series A Convertible Preferred Stock | (562) | — |
| Gain on extinguishment of Series A Convertible Preferred Stock | 222 | — |
| Deemed dividend of on Series C Preferred Stock | — | (123) |
| Net loss attributable to common stockholders | $(25,154) | $(20,416) |
| Net loss per common share, basic and diluted | $(15.65) | $(6,031.31) |
| Weighted average common shares outstanding, basic and diluted | 1,606,989 | 3,385 |
| Other comprehensive loss | ||
| Net loss | $(24,515) | $(11,901) |
| Change in cumulative translation adjustment | 57 | 310 |
| Total comprehensive loss | $(24,458) | $(11,591) |
| * | All common share data has been retroactively adjusted to effect reverse stock splits in 2023 and 2024 (see Note 1). |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.